专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050070719A1 Inhibitors of dipeptidyl peptidase iv 审中-公开
标题翻译：二肽基肽酶抑制剂
公开(公告)号：US20050070719A1
公开(公告)日：2005-03-31
申请号：US10499675
申请日：2002-12-26
申请人： Sergei Belyakov , Gregory Hamilton , David Hurst , Vincent Kalish , Weixing Li , Eric Wang , Douglas Wilkinson , Yong-Qian Wu , Weizheng Xu
发明人： Sergei Belyakov , Gregory Hamilton , David Hurst , Vincent Kalish , Weixing Li , Eric Wang , Douglas Wilkinson , Yong-Qian Wu , Weizheng Xu
IPC分类号： C07D295/18 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/404 , A61K31/426 , A61K31/427 , A61K31/4453 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K38/00 , A61K45/00 , A61P1/14 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P15/00 , A61P15/16 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/06 , A61P39/02 , A61P41/00 , A61P43/00 , C07D205/04 , C07D207/04 , C07D207/16 , C07D207/20 , C07D207/22 , C07D209/18 , C07D209/42 , C07D209/46 , C07D209/48 , C07D217/14 , C07D217/16 , C07D217/22 , C07D217/26 , C07D233/60 , C07D263/06 , C07D277/04 , C07D277/06 , C07D295/125 , C07D295/185 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D409/06 , C07D417/06 , C07K5/078 , C07K5/097
CPC分类号： C07D209/48 , A61K38/00 , C04B35/632 , C07D205/04 , C07D207/04 , C07D207/16 , C07D207/20 , C07D207/22 , C07D209/42 , C07D209/46 , C07D217/14 , C07D217/16 , C07D217/26 , C07D263/06 , C07D277/04 , C07D277/06 , C07D295/125 , C07D295/185 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D409/06 , C07D417/06 , C07K5/06156 , C07K5/0821
摘要： Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.
摘要翻译：提供了二肽基肽酶IV（DPP IV）的新型抑制剂，包含治疗有效量的新型DPP IV抑制剂的药物组合物，以及治疗医学病症的新方法。本文描述的DPP IV的新型抑制剂可用于治疗神经障碍，糖尿病，炎症性疾病如关节炎，肥胖症，骨质疏松症以及可用DPP IV抑制剂治疗的其他列举的病症。

2. 发明授权

US08329666B2 Compositions and methods for treating cancer 有权
标题翻译：用于治疗癌症的组合物和方法
公开(公告)号：US08329666B2
公开(公告)日：2012-12-11
申请号：US12755122
申请日：2010-04-06
申请人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
发明人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
IPC分类号： A61K31/706 , A61P35/00
CPC分类号： A61K45/06 , A61K31/551 , A61K31/7052 , A61K31/7068 , A61K2300/00
摘要： Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.
摘要翻译：本文提供了治疗癌症的方法，包括将抑制脱氨酶的化合物与地西他滨灭活化合物组合施用地西他滨。

3. 发明授权

US08324180B2 Compositions and methods for treating cancer 有权
公开(公告)号：US08324180B2
公开(公告)日：2012-12-04
申请号：US12755106
申请日：2010-04-06
申请人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
发明人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
IPC分类号： A61K31/7052 , A61P35/00 , C07H19/04
CPC分类号： C07H19/04 , A61K31/7052
摘要： Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.

4. 发明授权

US08329665B2 Compositions and methods for treating cancer 有权
标题翻译：用于治疗癌症的组合物和方法
公开(公告)号：US08329665B2
公开(公告)日：2012-12-11
申请号：US12755116
申请日：2010-04-06
申请人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
发明人： Sergei Belyakov , Bridget Duvall , Dana Ferraris , Gregory Hamilton , Mark Vaal
IPC分类号： A61K31/7072 , A61K31/7052 , A61P35/00 , A61P35/02
CPC分类号： A61K45/06 , A61K31/551 , A61K31/7052 , A61K31/706 , A61K31/7068 , A61K2300/00
摘要： Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
摘要翻译：本文提供了用于抑制负责灭活治疗化合物的脱氨酶的化合物及其使用方法。

5. 外观设计

USD904179S1 Table edge rail cover 有权
公开(公告)号：USD904179S1
公开(公告)日：2020-12-08
申请号：US29620429
申请日：2016-12-07
申请人： Gregory Hamilton , Patricia Hamilton
设计人： Gregory Hamilton , Patricia Hamilton
摘要： FIG. 1 is a front elevation view of a (TITLE), showing our new design;
FIG. 2 is a side elevation view thereof;
FIG. 3 is a top plan view thereof; and,
FIG. 4 is a bottom plan view thereof.
The broken lines in the drawings illustrate portions of the table edge rail cover which form no part of the claimed design.

6. 发明申请

US20050272780A1 Small molecule inhibitors of rotamase enzyme activity 失效
标题翻译：旋转异构酶活性的小分子抑制剂
公开(公告)号：US20050272780A1
公开(公告)日：2005-12-08
申请号：US11166220
申请日：2005-06-27
申请人： Gregory Hamilton , Joseph Steiner
发明人： Gregory Hamilton , Joseph Steiner
IPC分类号： C12N9/99 , A61K31/00 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/427 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K38/00 , A61K45/00 , A61P21/00 , A61P21/02 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/16 , A61P25/24 , A61P25/28 , A61P37/00 , A61P43/00 , C07B53/00 , C07D207/16 , C07D401/04 , C07D401/06 , C07D405/06 , C07D405/10 , C07D405/12 , C07D407/04 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D417/02 , C07D417/04 , C07D417/12 , C07K5/078 , C07D43/02 , C07D49/02
CPC分类号： C07D401/06 , A61K31/444 , C07D207/16 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
摘要： This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.
摘要翻译：本发明涉及对FKBP型免疫亲和素具有亲和性的神经营养的N-乙醛酰脯氨酰酯化合物，它们的制备和用作与免疫亲和素蛋白相关的酶活性的抑制剂，特别是肽基 - 脯氨酰异构酶或旋转异构酶活性的抑制剂。

7. 发明申请

US20060264433A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) 审中-公开
标题翻译：药物组合物作为二肽基肽酶-IV（DPP-IV）的抑制剂
公开(公告)号：US20060264433A1
公开(公告)日：2006-11-23
申请号：US11438881
申请日：2006-05-23
申请人： Bradley Backes , Gregory Hamilton , Hana Kopecka , Chunqiu Lai , Kenton Longenecker , David Madar , Zhonghua Pei , Kent Stewart , Thomas Von Geldern
发明人： Bradley Backes , Gregory Hamilton , Hana Kopecka , Chunqiu Lai , Kenton Longenecker , David Madar , Zhonghua Pei , Kent Stewart , Thomas Von Geldern
IPC分类号： A61K31/5377 , A61K31/506 , A61K31/502 , A61K31/496 , A61K31/53 , A61K31/4439 , A61K31/4025 , C07D413/02 , C07D409/02 , C07D403/02
CPC分类号： C07D403/14 , C07D207/14 , C07D401/12 , C07D401/14 , C07D403/04 , C07D409/14 , C07D413/14
摘要： The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
摘要翻译：本发明涉及抑制二肽基肽酶IV（DPP-IV）并且可用于预防或治疗糖尿病，特别是II型糖尿病以及高血糖症，综合征X，高胰岛素血症，肥胖症，动脉粥样硬化，各种免疫调节疾病，等疾病。

8. 发明申请

US20070117978A1 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase 审中-公开
标题翻译：对β-肾上腺素能受体和磷酸二酯酶具有抑制活性的强心药物
公开(公告)号：US20070117978A1
公开(公告)日：2007-05-24
申请号：US10547930
申请日：2003-12-23
申请人： Gregory Hamilton , Harry Leighton
发明人： Gregory Hamilton , Harry Leighton
IPC分类号： A61K31/519 , A61K31/502 , A61K31/501 , A61K31/4745 , A61K31/4704 , C07D487/04 , C07D403/02
CPC分类号： C07D215/227 , C07D233/70 , C07D487/04
摘要： The present invention provides compounds possessing inhibitory activity against (3-adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated and for treating cardiovascular disease, stroke, epilepsy, an ophthalmic disorder or migraine.
摘要翻译：本发明提供对3-肾上腺素能受体和磷酸二酯酶（PDE）具有抑制活性的化合物，包括3型磷酸二酯酶（PDE-3），本发明还提供包含这些化合物的药物组合物，制备这些化合物的方法和方法使用这种化合物来调节钙稳态，用于治疗涉及钙稳态失调的疾病，病症或病症，以及治疗心血管疾病，中风，癫痫，眼科障碍或偏头痛。

9. 发明申请

US20070066619A1 Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity 审中-公开
标题翻译：具有同时阻断L型钙通道并抑制磷酸二酯酶3型活性的化合物
公开(公告)号：US20070066619A1
公开(公告)日：2007-03-22
申请号：US11499397
申请日：2006-08-04
申请人： Gregory Hamilton , Harry Leighton , Jeff Bechard , Beth Allison , John Gibson
发明人： Gregory Hamilton , Harry Leighton , Jeff Bechard , Beth Allison , John Gibson
IPC分类号： A61K31/502 , A61K31/501 , A61K31/519 , A61K31/4745 , A61K31/4709 , A61K31/4439 , C07D487/04 , C07D471/02
CPC分类号： C07D401/04 , C07D211/90 , C07D213/85 , C07D237/04 , C07D401/12 , C07D487/04
摘要： The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
摘要翻译：本发明提供对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供包含这些化合物的药物组合物和使用这些化合物治疗心血管疾病，中风，癫痫，眼科障碍或偏头痛的方法。

10. 发明申请

US20070186283A1 Apparatus and method for providing program protection engineering, security management, and report preparation for sensitive and classified projects 有权
标题翻译：为敏感和分类项目提供程序保护工程，安全管理和报告准备的装置和方法
公开(公告)号：US20070186283A1
公开(公告)日：2007-08-09
申请号：US11347285
申请日：2006-02-06
申请人： Kenneth Brumbaugh , Howard Low , Gregory Hamilton , James Davis , Wendy Fan
发明人： Kenneth Brumbaugh , Howard Low , Gregory Hamilton , James Davis , Wendy Fan
IPC分类号： G06F11/00
CPC分类号： G06F21/577 , G06Q10/06 , G06Q10/06311
摘要： An apparatus and method using a program protection engineering (P2E) toolkit to provide program protection engineering, security management, and report preparation for sensitive and classified projects. The P2E toolkit is an implementation of security policies, procedures, and methodologies associated with acquisition programs. Acquisition programs may range from large-scale classified systems for the government to sensitive corporate acquisition programs focusing on company proprietary or intellectual property issues. Specifically, the P2E toolkit provides end-to-end program protection engineering, security management, and report preparation for sensitive and classified programs throughout the program lifecycle, and assists security professionals and program managers to make appropriate decisions to protect their acquisition programs from compromise due to foreign intelligence threats or corporate/industrial espionage. The P2E toolkit enhances the traditional program management concerns of technical performance, schedule, and cost, by adding lifecycle protection as in integral component.
摘要翻译：一种使用程序保护工程（P2E）工具包的设备和方法，用于为敏感和分类项目提供程序保护工程，安全管理和报告准备。 P2E工具包是与采购计划相关的安全策略，程序和方法的实现。收购计划可能范围从政府的大规模分类系统到专注于公司专有或知识产权问题的敏感企业收购计划。具体来说，P2E工具包在整个程序生命周期中为敏感和分类程序提供端到端程序保护工程，安全管理和报告准备，并协助安全专业人员和程序管理人员做出适当决策，以保护其采集程序免受妥协对外国情报威胁或企业/工业间谍活动。 P2E工具包通过将生命周期保护作为整体组件添加，增强了传统程序管理对技术性能，进度和成本的关注。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式